Changes in Hong Kong stocks | Pharmaceutical Juno-B (02126) rose more than 20% intraday, and CAR-T therapy reached the basic health insurance negotiation table for the first time

The Zhitong Finance App learned that Pharmaceutical Junuo B (02126) rose more than 20% in the intraday period. As of press release, it rose 17.72% to HK$2.79, with a turnover of HK$22.158,900.

According to the news, in 2026, the national health insurance talks achieved a “double catalogue” link between basic health insurance and commercial insurance for the first time, and million-yuan CAR-T therapy reached the basic health insurance negotiation table for the first time. Relying on the “Condition 5” policy, Heyuan Biotech and Pharmacomingju Noriki Orensai entered basic health insurance negotiations from the commercial insurance catalogue and adopted a two-track approach of “basic health insurance admission+commercial insurance expansion”. If the negotiations are successful, a new paradigm of medical insurance pricing for high-cost cell therapy will be established to greatly reduce the burden on patients.

It is worth noting that Pharmacovigenol recently announced that the supplementary application for Rikki Orenxol injections has been officially approved after marketing. The approval for the extension of the frozen storage period is based on complete process verification data support from Pharmaceutical Junuo. The study results confirmed that the storage period of frozen T-cells after sorting CD4/CD8 beads was extended to 36 months, so that Rickie Orenxol injection products that meet pre-set quality standards can still be produced stably as the starting material, further improving the flexibility of CAR-T production and scheduling, and providing more space for clinical individualized treatment options.